W O R K I N G

T O G E T H E R

P r o f i l e s o f C o l l a b o r a t i o n

A L Z H E I M E R ’ S D R U G D I S C O V E R Y F O U N D A T I O N 2 0 0 5 A N N U A L R E P O R T

• • •

S C I E N C E

Alzheimer’s disease (AD) is a tragic loss-of-mind illness that affects 1 of every 4 people over age 75, and their care-

givers. It also takes an enormous toll on society. At over $100 billion per year, AD is the third most costly disease

in the U.S. after heart disease and cancer. Currently, 18 million cases have been reported worldwide. In the com-

ing years, with baby boomers aging, the number of cases will triple. The devastating personal and societal costs of

AD can be reduced by developing new drugs. With just 4 modestly effective drugs on the market today that only

treat the symptoms of the disease but not the cause, it is imperative that our research efforts be accelerated.

P A G E 1

S I G N I F I C A N C E

T H E U R G E N T N E E D F O R D R U G S

While basic research generally funded by foundations and government seeks to find the causes of AD, new treat-

ments come from drug discovery research, where chemical compounds that will be used for pills are created.

Developing effective AD drugs will enable older persons to die with dignity and save billions in healthcare costs.

This is an achievable goal. The Institute for the Study of Aging (ISOA), an Estée Lauder family foundation found-

ed in 1998, and the Alzheimer’s Drug Discovery Foundation (ADDF), an affiliated public charity established in

2004, are committed to funding the development of new treatments for AD through venture philanthropy.

D I S C O V E R Y

Neurotrophins are naturally occurring proteins that can prevent and treat neuronal degener-

ation. These proteins are too large to be taken orally or to adequately penetrate the central

nervous system to be useful as drugs. The development of small compounds that mimic

the key parts of neurotrophins has been a much sought after goal. Support from the Institute

for the Study of Aging (ISOA) allowed us to launch a high risk program in which we

applied advanced drug modeling to develop the first drug-like small molecules capable of

preventing neural degeneration.

Frank Longo, MD, PhD Professor and Chair, Stanford University Department of Neurology and Neurological Sciences

P A G E 2

S U P P O R T

E V A L U A T I N G R I S K S A N D R E W A R D S

Given the high risk, but potentially high yield, approach of our research, it was quite difficult to obtain funding. The

ISOA has created an exceptional vehicle for funding where risks and benefits of innovative drug discovery

programs are explored in depth and in the context of translational research that is very different from traditional

foundations. In addition to their financial support, ISOA provides expert technical assistance that is unparalleled to

any other philanthropic organization. With their help, my lab is now testing our drug-like molecules in mice with AD.

P A G E 3

P H I L A N T H R O P Y

Beta-secretase has long been recognized as a main therapeutic target for the development

of drugs to treat AD. When my laboratory cloned beta-secretase and determined its basic

properties, the stage was set for actual drug development. We recognized that such devel-

opment would require organization and funding. Together with Arun Ghosh, we founded a

biotechnology company named Zapaq, with the mission to develop beta-secretase inhibitor

drugs. One of two initial sources of seed funding came from the ISOA.

Jordan Tang, PhD Chief Scientific Officer of Zapaq, and Chair of Medical Research, Oklahoma Medical Research Foundation

P A G E 4

R E T U R N S

B R I N G I N G N E W D R U G S T O M A R K E T

Their funding was critical for Zapaq because it allowed us to obtain business and legal assistance in setting up

the framework of the company. It also helped us to recruit key scientists and begin our research program, as well

as seek follow-on funding. Today, at three-years-old, Zapaq has stable financing from venture capital companies.

Its research team has used structure-based design to attain advanced drug candidates. Such programs afford opti-

mism that a drug candidate will be tested in human clinical trials in the near future. Without ISOA’s assistance,

it would have been difficult for our company to come into existence.

P A G E 5

Elan Pharmaceuticals is proud to be working with the Alzheimer’s Drug Discovery Foundation

(ADDF), an ISOA affiliated public charity, to support innovative drug discovery for AD. The

program that we collaboratively launched in 2005, Novel Approaches to Drug Discovery for

Alzheimer's Disease, seeks to identify and fund promising research in academic and biotech

labs around the world. Alliances such as these, among biotechnology companies, philanthro-

pies and academic institutions, are crucial to accelerating breakthrough therapies for AD.

Kelly Martin President & Chief Executive Officer, Elan Pharmaceuticals, Inc.

P A G E 6

C O L L A B O R A T I O N

C H A N G E

The ADDF utilizes a unique venture philanthropy model focused on drug discovery. For over 20 years, Elan has also

invested in adopting original approaches to disease modification in neurodegenerative diseases like AD. We have a

common goal — to help end the life-shattering disease that not only impacts patients but also their loved ones.

When we can combine our passion, energy and ingenuity, we create the opportunity to advance towards providing a

cure. By joining forces, we are increasing the chances of success and ultimately benefiting millions of people.

P A G E 7

C R E A T I N G O P P O R T U N I T I E S F O R S U C C E S S

P A G E 8

When we started the ISOA in 1998, our goal was to create a family foun-dation that would fund scientists pursuing drug discovery research for ADin hopes that we could find a better way to prevent and treat this horrificdisease. Through expert leadership, our Executive Director Howard Fillit,MD, has proven that providing this funding is not only necessary, but it alsoserves as a catalyst for scientists worldwide.

Over the years, requests for funding grew to the point where we were onlyable to support less than 10 percent of the proposals we received. With somany good ideas for new drugs going unfunded, we decided it was time toinvite others to work with us.

During spring 2004, we founded a public charity called the Alzheimer’sDrug Discovery Foundation (ADDF). By fall, we began in earnest to build partnerships. The response was extraordinary, making 2005 a banneryear of growth. We collaborated with several key organizations and raisedawareness about the importance of funding AD drug discovery.

In working with our new Board of Directors, who each have a personal connection to AD, we are developing innovative ways to educate the gener-al public. As we have learned over the past year, our best approach to con-quering AD is through working together. We encourage you to join us.

M E S S A G E F R O M A D D F C O - C H A I R P E R S O N S

Ronald LauderCo-Chairperson & Director

Leonard Lauder Co-Chairperson & Director

P A G E 9

During the 8 years that I was the primary caregiver for my beloved mother,I saw AD progress through many stages. At first, I wondered why this wonderful woman was changing and becoming a stranger to me. Then, thedisease became more obvious. Finally, it totally enveloped her and took herfrom me.

When I heard about ISOA and their sole mission of funding drug discoveryresearch for AD, I was very impressed. As I learned more about their accom-plishments it led me to think that this was the type of organization that I should align with, to do whatever I can in the fight against this dreaded disease.

Since becoming President of the ADDF Board of Directors, it has been myvision to inspire people who have witnessed the tragedy of AD to work withus. We also need to increase the public’s awareness and understanding ofwhy drug discovery is important to finding a cure; and the degree to whichAD impacts patients, families, our healthcare system and economy.

I look forward to working with others whose goals are similar to mine. The only way we can end the nightmare of AD is to collectively support scientists in their research efforts to discover and develop new drugs.

M E S S A G E F R O M A D D F P R E S I D E N T

Nancy CorzinePresident & Director

P A G E 1 0

A D D F B O A R D M E M B E R S

Losing my mother to AD over 7 years was

difficult to watch. The sad fact was this vibrant

lady slowly left me and there was nothing I

could do. In my effort to get even, I discovered

the ADDF. Driven by a singular mission and

relentless professional management, ADDF

is the most effective charity working towards

solving one of the most challenging

diseases of the 21st Century.”

John Cooney is a private investor who was Founder

and Chief Executive Officer of CRC Incorporated,

the largest independently owned property and

casualty insurance wholesaler in the United

States. In 2002, CRC was sold to BBT, America’s

9th largest bank holding company. Mr. Cooney

earned his BS degree in Business from Samford

University of Birmingham, AL. He and wife Liz

reside in Alabama, New York and Switzerland.

Having someone close to me recently

diagnosed with dementia has changed my life.

Learning about the ADDF and meeting others

who have witnessed this loss-of-mind illness

has been a blessing. Now that I have a better

understanding of memory loss diseases, I am

determined to make a difference. Working with

the ADDF Board to fund those on the cutting

edge of a cure is my top priority.”

Joy Fishman is the former Executive Director

of the Pritikin Longevity Center of Miami Beach,

where she oversaw the operations of the world

famous diet and exercise program. Ms. Fishman

holds a MS degree in Psychotherapy and a BS

degree in Psychology from Barry University of

Miami, FL. She and husband Jack reside in New

York and Florida.

Joy FishmanDirector

John CooneyDirector

“ “

P A G E 1 1

I think ADDF’s investment model is a

brilliant way to run a public charity. Using

for-profit business practices and recycling

return on investment is a smart strategy for

making the most out of limited dollars.

Knowing how AD has affected my wife’s family,

it made sense to join forces with the ADDF

Board and help them increase their likelihood

of success. I welcome others to do the same.”

Jon Rotenstreich is a managing partner of

RF Partners, a financial consulting and invest-

ment firm. He is also the founding principal and

Chairman of Bayer Properties, a real estate

development company. Mr. Rotenstreich is a

graduate of the University of Alabama (UA) and

sits on many boards including UA’s President’s

Cabinet. He and wife Susan reside in New York

and Wyoming.

One of the last unmet medical needs in our

society is a disease-modifying drug for AD. The

ADDF dedicates itself toward this goal, which

will improve the quality of life for millions of

people. With my personal knowledge of AD and

my experience in the venture capital arena, I

believe that I can help the ADDF, but it will

take more than a few of us to succeed. Join

us in funding this important goal.”

Robert McNeil, PhD, has over 25 years experience

as an investor and management participant in

seed and early-stage biomedical companies.

He founded Sanderling Ventures in 1979, and

serves as its Managing Director and Chair of the

Partnership Committee. Dr. McNeil earned his

PhD in molecular biology, biochemistry and genet-

ics from the University of California, Irvine. He

and wife Deborah reside in California and Maine.

Jon RotenstreichDirector

Robert McNeil, PhDDirector

“ “

P A G E 1 2

M E S S A G E F R O M T H E E X E C U T I V E D I R E C T O R

Howard Fillit, MDExecutive Director

ISOA and ADDF share a common mission: to fund drug discovery for AD and cognitive aging. Employing a biomedical venture philanthropymodel since 1998, we have awarded $24 million for 143 programs and conferences worldwide.

Results show that our model works. ISOA-funded scientists created newclasses of drugs in development for AD, screened millions of compounds,identified hundreds of leads, and demonstrated pre-clinical proof-of-concept. Their programs advanced from early-stage chemistry to clinical trials, licensing deals, company formation, late-stage financing, and publicofferings. We have also received returns on our investments.

A prime example is Allon Therapeutics, Inc. After awarding a pre-clinical discovery research grant to Illana Gozes, PhD, at Tel Aviv University andreceiving promising outcomes, we gave her strategic management assistanceand a loan of $253,100 to found Allon in 2002. Today, the company is trading on the Toronto Stock Exchange and conducting Phase II clinical trials for AD and cognitive impairment after coronary artery bypass surgery.In December 2005, ISOA received the return of its loan and recycled it forother research.

Unfortunately, $24 million is not enough, and ISOA cannot fund the vastmajority of proposals it receives. So we founded the ADDF in 2004 to enablethe public to work with us. ISOA pays 90 percent of ADDF’s overhead,ensuring that all donations directly fund drug discovery research. This pri-vate foundation-public charity partnership proved highly effective in 2005.

P A G E 1 3

A D D F I S A N O R G A N I Z A T I O N O F

e n t r e p r e n e u r s

D E D I C A T E D T O A C C E L E R A T I N G A D D R U G D I S C O V E R Y

T H R O U G H V E N T U R E P H I L A N T H R O P Y .

We collaborated with Elan Pharmaceuticals to advance our mutual missionof discovering new drugs for AD. The program received an overwhelmingresponse of 45 proposals from 12 countries, but we were only able to fund4. We also partnered with the National Institute on Aging (NIA) and established another AD drug discovery program that received 45 proposals.The NIA funded 5 and we will fund 3. These responses underscore the greatneed for funding.

We are concerned about preventing cognitive decline as well as AD. To pro-mote cognitive health in elderly persons, we partnered with PacfiCare HealthSystems to create a Cognitive Vitality Program that is now available to180,000 people. To improve the care of AD patients, we are developing clinical practice guidelines with funding from Forest Laboratories.

We established the ADDF Board of Directors, Advisory Council andBusiness Development Committee, and are thankful for their commitment.We were fortunate to have many corporations, foundations and individualscontributing to our first fundraising program, resulting in raising almost$2.5 million.

As a geriatrician who has cared for thousands of people with AD, I know the tremendous burden of this illness. As a neuroscientist, I am certain that wecan successfully develop effective AD drugs within 5-10 years. This historicaccomplishment will transform human aging. We need your help to insurethat it happens.

P A G E 1 4

S T A F F

Howard M. Fillit, MDExecutive Director

Suzanne Grossberg, MADirector of Development

Monika HalarewiczCommunications Associate

Filomena GomesGrants Writer

Wendy RamosGrants and Database Manager

S C I E N T I F I C R E V I E W B O A R D

Paul S. Aisen, MD Georgetown University Medical Center Washington, DC

Larry D. Altstiel, MD, PhD Schwarz Biosciences, Inc. Research Triangle Park, NC

Ottavio Arancio, MD, PhD Columbia University New York, NY

Sanjay Asthana, MD University of WisconsinMadison Medical School Madison, WI

Theodore Bashore, PhD University of NorthernColorado Greeley, CO

Paul E. Bendheim, MD Banner Good Samaritan Medical Center Phoenix, AZ

• • •

A D D F B O A R D O F D I R E C T O R S

Leonard A. LauderCo-Chairperson and Director

Ronald S. LauderCo-Chairperson and Director

Nancy CorzinePresident and Director

Howard Fillit, MDExecutive Director and Director

I S O A B O A R D O F D I R E C T O R S

Suzanne Grossberg, MASecretary

Joan KrupskasTreasurer

John CooneyDirector

• • •

• • •

Colin B. Bier, PhD ABA BioResearch Inc. Ville St. LaurentQuebec, Canada

Lester I. Binder, PhDNorthwestern University Medical School Chicago, IL

Joy FishmanDirector

Robert McNeil, PhDDirector

Jon RotenstreichDirector

A D D F A D V I S O R Y C O U N C I L

Howard CoxPartnerGreylock

John Rowe, MDPresident and Chief Executive OfficerAetna, Inc.

Andrew Schiff, MDManaging DirectorPerseus-SorrosBiopharmaceutical Fund, L.P.

• • •

A D D F B U S I N E S S D E V E L O P M E N T C O M M I T T E E

Nancy Corzine – Chair

Howard Fillit, MD

Liz Cooney

Joy Fishman

Suzanne Grossberg, MA

Monika Halarewicz

Kate Furman Pasik

Leslye Sugar

• • •

Susan Tane

Amy Treitel

Peggy QuirozExecutive Coordinator

Howard Fillit, MDExecutive Director and Director

Suzanne Grossberg, MASecretary

Joan KrupskasTreasurer

Robert N. Butler, MDDirector

Barbara J. Dalton, PhDDirector

Lanny Edelsohn, MDDirector

Allan Green, MD, PhD, JDDirector

Julia P. GregoryDirector

Elias K. Michaelis, MD, PhDDirector

Estée LauderFounder and Honorary Director

Leonard A. LauderCo-President and Director

Ronald S. LauderCo-President and Director

P A G E 1 5

James E. Birren, PhD UCLA Center on Aging Los Angeles, CA

Roberta Diaz Brinton, PhD University of SouthernCalifornia Los Angeles, CA

Jerry Buccafusco, PhD

Prime Behavior TestingLaboratories, Inc. Augusta, GA

Luc Buee, PhD INSERM U422 (French National Institute for Health and Medical Research) Lille, France

Anthony Cerami, PhDWarren Pharmaceuticals Ossining, NY

Greg M. Cole, PhD VA Medical Center Sepulveda, CA

Joseph T. Coyle, MD Harvard Medical School Belmont, MA

Suzanne Craft, PhD Seattle Institute for Biomedicaland Clinical Research Seattle, WA

Keith A. Crutcher, PhD University of Cincinnati Cincinnati, OH

Jeffrey L. Cummings, MDUCLA School of Medicine Los Angeles, CA

Charles S. DeCarli, MD University of California, DavisSacramento, CA

Richard Di Rocco, PhD, LLC

Secant Pharma

Karen Duff, PhD Nathan Kline Institute Orangeburg, NY

Christopher B. Eckman, PhD

Mayo Clinic JacksonvilleJacksonville, FL

Elizabeth Edgerly, PhD Alzheimer’s Association ofNorthern California andNorthern Nevada Mountain View, CA

Alan Faden, MD Georgetown University School of Medicine Washington, DC

Howard Feldman, MD University of British Columbia Hospital Vancouver, BCCanada

Kevin Felsenstein, PhD Johnson & JohnsonPharmaceutical Research &Development Titusville, NJ

Avraham Fisher, PhD Israel Institute for Biological Research Ness-Ziona, Israel

Nicholas Charles Ilya Fox, PhDDementia Research Centre London, UK

Blas Frangione, MD, PhD NYU School of Medicine New York, NY

Richard A. Frank, MD, PhD GE Healthcare Princeton, NJ

Paul E. Fraser, PhDUniversity of Toronto Toronto, Ontario Canada

Robert P. Friedland, MD Case Western Reserve UniversitySchool of Medicine Cleveland, OH

George Fulop, MDNeedham & Company, Inc. New York, NY

Douglas R. Galasko, MD University of California, San Diego La Jolla, CA

Elkan Gamzu, PhD enERGetics Newton, MA

Jack Gauldie, PhD McMaster University Hamilton, OntarioCanada

David S. Geldmacher, MD Case Western Reserve UniversitySchool of Medicine Cleveland, OH

Gunda I. Georg, PhD University of Kansas Lawrence, KS

Ezio Giacobini, MD, PhD Geneva University HospitalsSwitzerland

Alison M. Goate, PhD Washington University School of Medicine St. Louis, MO

Michael Gold, MD Johnson & JohnsonPharmaceutical Research & Development Titusville, NJ

Paul E. Gold, PhD University of Illinois at Urbana-Champaign Champaign, IL

Gunnar K. Gouras, MD Weill Medical College of Cornell University New York, NY

Illana Gozes, PhD Tel Aviv University Tel Aviv, Israel

Barry D. Greenberg, PhDAstraZeneca PharmaceuticalsWillmington, DE

Michael Grundman, MD Elan Pharmaceuticals San Diego, CA

John Hardy, PhD National Institute on AgingBethesda, MD

Mitchell Harman, MD, PhDKronos Foundation Phoenix, AZ

Joseph A. Helpern, PhD NYU School of Medicine New York, NY

Orest Hurko, MD Wyeth ResearchCollegeville, PA

Michael Hutton, PhD Mayo Clinic JacksonvilleJacksonville, FL

Nadeem Ishaque, PhD GE Corporate Research &Development Niskayuna, NY

Clifford Jack, MD Mayo Clinic College of Medicine Rochester, MN

William Jagust, MD University of California,Berkeley Berkeley, CA

Jeffrey Kaye, PhD Oregon Health & Science UniversityPortland, OR

Judith Kelleher-Andersson,PhD Neuronascent, Inc. Clarksville, MD

Robert Kisilevsky, MD, PhDFRCPCQueens University Kingston, Ontario Canada

David Knopman, MD Mayo Clinic College of Medicine Rochester, MN

Amos Korczyn, MD, MScTel Aviv University Tel Aviv, Israel

Kenneth Kosik, MD Brigham and Women’s HospitalBoston, MA

Dora M. Kovacs, PhDMassachusetts General HospitalCharlestown, MA

Alan P. Kozikowski, PhD Acenta Arlington, VA

Arthur F. Kramer, PhDUniversity of Illinois Urbana, IL

Lewis H. Kuller, PhD University of Pittsburgh Medical Center Pittsburgh, PA

Frank M. LaFerla, PhD University of California, IrvineIrvine, CA

Debomoy Lahiri, PhD Indiana University School of Medicine Indianapolis, IN

Gary Landreth, PhD Case Western Reserve UniversitySchool of Medicine Cleveland, OH

Lit-Fui Lau, PhD Pfizer Inc. Groton, CT

Virginia M. Y. Lee, PhD University of PennsylvaniaPhiladelphia, PA

Frank M. Longo, MD, PhDUniversity of North Carolina School of Medicine Chapel Hill, NC

Rebekah Loy, PhD University of Rochester Rochester, NY

Eckhard Mandelkow, PhD Max-Planck-Unit forStructural Molecular Biology Hamburg, Germany

Eva-Maria Mandelkow, MD, PhD Max-Planck-Unit forStructural Molecular Biology Hamburg, Germany

Charles J. Manly, PhD Neurogen Corporation Branford, CT

P A G E 1 6

Suzana Petanceska, PhDNIA-NNABethesda, MD

Ronald C. Petersen, MD, PhD Mayo Clinic College of Medicine Rochester, MN

William Potter, MD, PhD Lilly Research LaboratoriesIndianapolis, IN

Donald L. Price, MD Johns Hopkins University Baltimore, MD

Ram Ramabhadran, PhDEnvironmental Protection Agency Research Triangle Park, NC

G. William Rebeck, PhDGeorgetown University School of Medicine Washington, DC

George W. Rebok, PhD Johns Hopkins University Baltimore, MD

Lorenzo Refolo, PhD NINDS Rockville, MD

Eric Reiman, MD Banner Good Samaritan Medical Center Phoenix, AZ

Peter B. Reiner, VMD, PhDUniversity of British Columbia Hospital Vancouver, BCCanada

Nikolaos K. Robakis, PhD Mount Sinai School ofMedicine Bronx, NY

Jack T. Rogers, PhD Massachusetts General HospitalCharlestown, MA

Joseph Rogers, PhD Sun Health Research Institute Sun City, AZ

Martin Rossor, MD National Hospital forNeurology and NeurosurgeryLondon, England

Barbara Sahagan, PhD Pfizer Inc. Groton, CT

Stephen Salloway, MD Butler Hospital Providence, RI

Kumar Sambamurti, PhD Medical University of South Carolina Charleston, SC

Eliezer Masliah, PhD University of California, San Diego La Jolla, CA

Doug Matthews, PhD University of Memphis Memphis, TN

Patrick C. May, PhD Eli Lilly and Company Indianapolis, IN

Richard Mayeux, MD, MScColumbia University New York, NY

Bruce S. McEwen, PhD The Rockefeller University New York, NY

James L. McGaugh, PhD University of California, IrvineIrvine, CA

Elias K. Michaelis, MD, PhDUniversity of Kansas Lawrence, KS

Mary L. Michaelis, PhD University of Kansas Lawrence, KS

Myron Miller, MD Sinai Hospital of BaltimoreBaltimore, MD

Hans Joerg Moebius, PhD Merz and Company Germany

Richard Mohs, PhD Lilly Research LaboratoriesIndianapolis, IN

Perry B. Molinoff, MD University of PennsylvaniaPhiladelphia, PA

Dave Morgan, PhD University of South Florida Tampa, FL

John C. Morris, MD Washington University School of Medicine St. Louis, MO

David T. Nash, MDNIA-NNABethesda, MD

Alan W. O’Connell, PhD Seroba Bioventures Ireland

Burton Orlando, RPh Oxford Health Plus Trumbull, CT

George Perry, PhD Case Western Reserve UniversitySchool of Medicine Cleveland, OH

Philip Scheltens, PhD VU University Medical Center Amsterdam, The Netherlands

Alexander Scriabine, MD Yale University Medical School New Haven, CT

Kenneth Selzer, MD, PhD NIA-NNABethesda, MD

Einar M. Sigurdsson, PhD NYU School of Medicine New York, NY

Israel Silman, PhD The Weizmann Institute of Science Rehovot, Israel

Ely Simon, MD NeuroTrax Corporation Bayside, NY

Scott A. Small, MD Columbia University New York, NY

Gary W. Small, MD UCLA NeuropsychiatricInstitute Los Angeles, CA

Jonathan D. Smith, PhD The Cleveland Clinic FoundationCleveland, OH

Reisa Sperling, MD Harvard Medical School Belmont, MA

Ross L. Stein, PhD Brigham and Women’s HospitalBoston, MA

Yaakov Stern, PhD Columbia University New York, NY

Joel L. Sussman, PhD The Weizmann Institute of Science Rehovot, Israel

Walter Szarek, PhD Queens University Kingston, OntarioCanada

Jordan Tang, PhD Oklahoma Medical Research Foundation Oklahoma City, OK

Rudolph E. Tanzi, PhDMassachusetts General HospitalCharlestown, MA

Pierre Tariot, MD University of Rochester Rochester, NY

Tina L. Tekirian, PhD The National Cancer InstituteFrederick, MD

Andrea J. Tenner, PhD University of California, IrvineIrvine, CA

Leon J. Thal, MD University of California, San Diego La Jolla, CA

John Trojanowski, MD, PhDUniversity of PennsylvaniaPhiladelphia, PA

Tim Tully, PhD Helicon Therapeutics Cold Spring Harbor, NY

Mark H. Tuszynski, MD University of California, San Diego La Jolla, CA

Axel Unterbeck, PhD Oxford Bioscience PartnersBoston, MA

Linda Van Eldik, PhDNorthwestern University Medical School Chicago, IL

Nicolaas Verhoeff, MD, PhD University of Toronto Toronto, Ontario Canada

Anabella Villalobos, PhD Pfizer Inc. Groton, CT

Tom Von Sternberg, MDHealthPartners Minneapolis, MN

Michael W. Weiner, MD University of California, San Diego La Jolla, CA

Harel Weinstein, PhD Weill Medical College of Cornell University New York, NY

Marta Weinstock-Rosin, PhDHebrew University Medical Centre Jerusalem, Israel

Peter Whitehouse, MD, PhD Case Western Reserve UniversitySchool of Medicine Cleveland, OH

David Wilson, PhD Brigham and Women’s HospitalBoston, MA

Manfred Windisch, PhD JSW-Research Forschungslabor GmbH Graz, Austria

Thomas Wisniewski, MD NYU School of Medicine New York, NY

P A G E 1 7

Julie Eskay-Eagle September Ventures LLC Cos Cob, CT

Stephen M. Goldberg, PhD The Channel Group New York, NY

Stephen M. Goodman, Esq.Pryor Cashman Sherman & Flynn, LLP New York, NY

Elaine Jones, PhDEuclidSR Partners New York, NY

Perry Karsen Celgene Corporation Summit, NJ

Glenn J. Kline Academy Funds Research Triangle Park, NC

Larry Kunstadt, PhDvFinance Investments, Inc. New York, NY

John K. Clarke Cardinal Partners Princeton, NJ

Mark A. Cochran, PhD NeuroVentures Capital, LLC Charlottesville, VA

Matthew S. Crawford Cockrell Interests, Inc. Houston, TX

Barbara J. Dalton, PhD EuclidSR Partners New York, NY

Steven G. Dickman CBT Advisors Cambridge, MA

Jeff Dobro, MD Creative Medical Management, Inc. Boonton Twp., NJ

Emer Leahy, PhD Psychogenics Inc. Hawthorne, NY

Michael Lytton, PhDOxford Bioscience PartnersBoston, MA

Robert G. Nagro ITF Global Partners New York, NY

Daniel J. O’ConnellNeuroVentures Capital, LLCCharlottesville, VA

William Paiva Chisholm Private Capital Tulsa, OK

Lynne H. Parker, PhDTrillium Medical Ventures, LLC New York, NY

Debra Peattie, PhDValeo Medical Inc. Concord, MA

Cathrin Petty Apax Partners & Co. London, England

Rana Quraishi, PhDStandard & Poors New York, NY

Cheryl V. Reicin, PhDTorysToronto, OntarioCanada

David W. Summa Acumen Pharmaceuticals, Inc.Glenview, IL

John Tallman Helicon Therapeutics Cold Spring Harbor, NY

Doug A. Zingale Greenberg Traurig, LLP Boston, MA

B U S I N E S S A D V I S O R Y B O A R D

F U N D E D P R O G R A M S

D r u g D i s c o v e r y

• • •

• • •

Ottavio Arancio, MD, PhDNathan Kline InstituteOrangeburg, NYCalpains: A Treatment ofAlzheimer’s DiseaseAward: $121,126Duration: 2000 – 2001

Columbia UniversityNew York, NY Calpain Inhibitor: A Treatmentof Alzheimer’s Disease - Part 2Award: $88,205 Duration: 2003 – 2005

Etienne-Emile Baulieu, PhDMAPREGLe Kremlin-Bicetre Cedex France Control of MicrotubuleAssembly in the NervousSystem: Novel Approach for thePrevention and Treatment ofNeurodegenerative DiseasesAward: $150,000 Duration: 2002 – 2003

Joseph K. Belanoff, MD Corcept Therapeutics, Inc. Menlo Park, CA Slowing the Progression of Cognitive Decline inAlzheimer’s Disease UsingMifepristoneAward: $462,929 Duration: 2001 – 2003

Dale E. Bredesen, PhDBuck Institute for Age Research Novato, CA Development of Drugs for aNew Therapeutic Target inAlzheimer’s DiseaseAward: $100,000 Duration: 2002 – 2003

Screening for Alzheimer’sTherapeutics Based on a Novel TargetAward: $100,000 Duration: 2004

Roberta Diaz Brinton, PhDUniversity of SouthernCaliforniaLos Angeles, CA Allopregnanolone as aNeurogenic Factor for Recovery of Neurons inAlzheimer’s DiseaseAward: $122,661 Duration: 2005 – 2006

Jerry Buccafusco, PhD Prime Behavior TestingLaboratories, Inc. Augusta, GA A Computer-Assisted CognitiveTest Battery for Aged MonkeyAward: $112,947 Duration: 2001 – 2003

Novel Properties of Analogs ofCholine for the Treatment ofNeurodegenerative DiseasesAward: $259,651 Duration: 2003 – 2005

Luc Buee, PhD INSERM U422 (FrenchNational Institute for Healthand Medical Research)Lille, France Towards Pin1 Inhibitors in the Treatment of Alzheimer’s DiseaseAward: $85,000 Duration: 2003 – 2004

Anne Cataldo, PhDMcLean Hospital/HarvardMedical SchoolBelmont, MA A Novel Method of Cell-Mediated Therapy forAlzheimer’s DiseaseAward: $75,000 Duration: 2005 – 2006

Michael W. Wolfe, PhD Brigham and Women’s Hospital Boston, MA

Tony Wyss-Coray, PhD Stanford University Stanford, CA

Austin Yang, PhD University of SouthernCalifornia Los Angeles, CA

Mousa B.H. Youdim, PhD Technion Haifa, Israel

P A G E 1 8

Michael Hutton, PhDMayo Clinic JacksonvilleJacksonville, FL In Vivo Testing of Compoundsthat Block the Development ofNeurofibrillary Tau PathologyAward: $196,662Duration: 2004 – 2006

Khalid Iqbal, PhD NY State Institute for Basic Research inDevelopmental DisabilitiesNew York, NY Screening Assays to InhibitAlzheimer NeurofibrillaryDegenerationAward: $528,869Duration: 2000 – 2004

Lee-Way Jin, MD, PhDUniversity of WashingtonSeattle, WA The Amelioration of A-BetaAggregation and Cell Toxicityby Tricyclic Pyrone CompoundsAward: $50,000 Duration: 2000 – 2001

June KinoshitaAlzheimer Research Forum FoundationWaltham, MA Alzheimer CheminformaticsResourceAward: $60,275 Duration: 2004 – 2006

Robert Kisilevsky, MD, PhDFRCPC Queens UniversityKingston, OntarioCanada Novel GlycosaminoglycanPrecursors As Anti-AmyloidAgentsAward: $245,300 Duration: 2000 – 2003

Novel Glycosaminoglycan(GAG) Precursors as Anti-Amyloid Agents - Part 2Award: $191,220 Duration: 2003 – 2004

Kenneth Kosik, MD Brigham and Women’s Hospital Boston, MA Identifying Drugs that InhibitKinase-Induced Dissociation ofTau from MicrotubublesAward: $130,000 Duration: 2001 – 2002

The Development of CDK5 InhibitorsAward: $199,000 Duration: 2004 – 2005

Siew Yeen Chai, PhDHoward Florey InstituteAustralia IRAP - Novel Target for theDevelopment of Memory-Enhancing AgentsAward: $82,000Duration: 2005 – 2006

Christopher B. Eckman, PhD Mayo Clinic JacksonvilleJacksonville, FL Herbal Extracts that Reduce A-Beta Peptide AccumulationAward: $127,567 Duration: 2001 – 2002

Natural Product Extracts that Reduce A-Beta PeptideAccumulationAward: $250,000 Duration: 2002 – 2004

Alan Faden, MD Georgetown University School of MedicineWashington, DC Modulation of Beta-AmyloidInduced Neuronal Apoptosis by Selective Activation of Metabotrophic Glutamate ReceptorsAward: $100,000 Duration: 2001 – 2005

Avraham Fisher, PhDIsrael Institute for Biological ResearchNess-Ziona, Israel Novel M1 Muscarinic Agonists:From Treatment TowardDelaying Progression ofAlzheimer’s DiseaseAward: $450,000 Duration: 1999 – 2002

Illana Gozes, PhD Tel Aviv UniversityTel Aviv, IsraelIsrael Femtomolar-ActingNeuroprotective Peptides:Application for Inhibition ofNeurodegenerative DiseaseAward: $220,000 Duration: 1999 – 2001

Allon Therapeutics, Inc. Vancouver, BC Canada Alzheimer’s Disease Biotech ProgramAward: $253,100 Duration: 2002 – 2003

Dora M. Kovacs, PhDMassachusetts General HospitalCharlestown, MA Effect of ACAT Inhibition on A-Beta Levels in PS1-APPTransgenic MiceAward: $125,000Duration: 2002 – 2004

Grant A. Krafft, PhDAcumen Pharmaceuticals, Inc.Glenview, IL High Throughput Screens forADDL-Blocker CompoundsAward: $133,493 Duration: 2003 – 2004

Daniel Laskowitz, PhDDuke University Medical CenterDurham, NC The Effect of ApoE MimeticTherapeutic Peptide in aMurine Model of AD.Award: $102,364 Duration: 2004 – 2005

An ApoE-Derived TherapeuticImproves AD Pathology in aMurine Model following HeadInjury - Year 2Award: $93,449 Duration: 2005 – 2006

Sebastian Lazareno, PhDMedical Research Council TechnologyLondon, England Development of SelectiveAllosteric Enhancers at HumanMuscarinic ReceptorsAward: $473,626 Duration: 2001 – 2003

Edward D. Levin, PhDDuke University MedicalCenterDurham, NC EC-SOD Protection fromAging-Induced CognitiveDeficits Due to Oxidative StressAward: $52,775 Duration: 2003 – 2004

Stuart A. Lipton, PhDNeuromolecular, Inc. Mill Valley, CADrug Development Plan forNitro-Memantine (Memantine-ONO 2) DerivativesAward: $244,700 Duration: 2004 – 2006

Frank M. Longo, MD, PhDUniversity of North CarolinaSchool of MedicineChapel Hill, NC Alzheimer’s Therapeutics:Neurotrophin Small Molecule MimeticsAward: $521,517 Duration: 2000 – 2004

BDNF Small MoleculeMimeticsAward: $162,500 Duration: 2004 – 2005

NGF Small Molecule Mimetics:Preclinical StudiesAward: $150,000 Duration: 2005 – 2006

Rebekah Loy, PhDUniversity of RochesterRochester, NY Valproate and Lithium toInhibit Tau PathophysiologyAward: $115,309 Duration: 2002 – 2004

Eckhard Mandelkow, PhDMax-Planck-Unit forStructural Molecular BiologyHamburg, Germany Search for Inhibitors of Tau AggregationAward: $156,000 Duration: 2003 – 2004

Search for Inhibitors of Tau AggregationAward: $159,500 Duration: 2005 – 2006

Marcos A. Marques, PhD ApoLogic, Inc. Cincinnati, OH Novel Drug Target inAlzheimer’s DiseaseAward: $145,395 Duration: 2002 – 2003

Yasuji Matsuoka, PhDGeorgetown University Medical CenterWashington, DC Development of Abeta-BindingAgents for Abeta Sequestration TherapyAward: $98,500 Duration: 2003 – 2004

Simon Melov, PhD Buck Institute for Age ResearchNovato, CA Potential Therapeutics forAlzheimer’s DiseaseAward: $97,987 Duration: 2001 – 2004

P A G E 1 9

Peter B. Reiner, VMD, PhD Active Pass PharmaceuticalsVancouver, BC Canada Brain-Expressed ABCTransporters as Targets for AD TherapeuticsAward: $150,000 Duration: 2000 – 2001

Elliott Richelson, MD Mayo Clinic JacksonvilleJacksonville, FL Peptide Nucleic Acids Targeted to the AmyloidPrecursor ProteinAward: $200,000 Duration: 2001 – 2003

Jack T. Rogers, PhDMassachusetts General HospitalCharlestown, MA A New Translational RegulatoryTarget in the Alzheimer’s APP TranscriptAward: $100,000 Duration: 2000 – 2002

Alzheimer’s Disease DrugDiscovery Targeted to the APP-mRNA 5’Untranslated RegionAward: $96,734Duration: 2001 – 2003

Small Molecule Drug DiscoveryTargeted To The Alzheimer’sAPP-mRNA 5’ Untranslated RegionAward: $100,000 Duration: 2003 – 2005

Kumar Sambamurti, PhDMedical University of South CarolinaCharleston, SC Evaluation of GPI-AnchoredProteins as Targets forInhibition of Beta-SecretaseAward: $200,000 Duration: 2000 – 2002

Steven Schreiber, MD University of California, IrvineIrvine, CA Efficacy of the HistoneDeacetylase Inhibitor, SAHA,in AD Transgenic Mice- AProof-of-Concept Study Award: $130,000 Duration: 2006 – 2007

Michael L. Shelanski, MD, PhD Columbia UniversityNew York, NY Pharmacological Reversal of theBehavioral and ElectricalSequelae of A-Beta DepositionAward: $50,000 Duration: 2004 – 2005

William S. Messer, Jr., PhD University of ToledoToledo, OH Development of SelectiveMuscarinic Agonists for the Treatment of Alzheimer’s DiseaseAward: $267,066 Duration: 2000 – 2001

Mary L. Michaelis, PhDUniversity of KansasLawrence, KS Microtubule - Stabilizing Drugs for Alzheimer’s DiseaseAward: $300,248Duration: 1999 – 2003

In Vivo Analysis of Effects ofMicrotubule-Stabilizing Drugsin Tau Mutant MiceAward: $258,352 Duration: 2003 – 2006

Suzana Petanceska, PhDNathan Kline InstituteOrangeburg, NYPharmacogenetic Effects ofHuman apoE on the Amyloid-Reducing Activity of CholesterolLowering Drugs in a Transgenic Mouse Model forAlzheimer’s DiseaseAward: $360,742 Duration: 2000 – 2003

Efficacy of Oral HeparinTreatment for Alzheimer’s DiseaseAward: $98,563 Duration: 2003 – 2004

Leonard Petrucelli, PhDMayo Clinic JacksonvilleJacksonville, FL Hsp70 Activity and Tau ATherapeutic TargetAward: $125,000 Duration: 2004 – 2005

Ram Ramabhadran, PhD Tranzyme Pharma, Inc. Research Triangle Park, NC Cell Culture Models andAnimal Models of Alzheimer’s DiseaseAward: $493,550 Duration: 2003 – 2005

Ciaran M. Regan, PhD, DScUniversity College DublinBelfield, DublinIreland Determination of the Effect ofChronic Administration ofABS-205 on Morris WaterMaze Learning in the Aged RatAward: $50,000 Duration: 2000

Jonathan D. Smith, PhDThe Cleveland ClinicFoundationCleveland, OH Estrogen and ApoE; Interactionand Effect on Pathogenesis in a Mouse Model ofAlzheimer’s DiseaseAward: $416,130 Duration: 1999 – 2002

Drug Discovery: EstrogenRelated Compounds in MouseModels of Alzheimer’s DiseaseAward: $90,000 Duration: 2003 – 2004

Beka Solomon, PhD Tel Aviv UniversityTel Aviv, Israel A Novel Approach TowardsVaccination Against AlzheimerBeta-Amyloid PeptideAward: $100,000 Duration: 2002 – 2004

Wolfgang J. Streit, PhDUniversity of FloridaGainesville, FL Role of Fractalkine inRegulating NeuronmicrogliaInteractionsAward: $126,492 Duration: 2003 – 2005

Sidney Strickland, PhDThe Rockefeller UniversityNew York, NY Analysis of the Role to tPAand Plasmino(gen) inAlzheimer’s DiseaseAward: $256,480 Duration: 2001 – 2003

Stephen M. Strittmater, PhDYale University Medical SchoolNew Haven, CT Nogo Antagonists in AxonRegeneration and PlasticityAward: $267,928 Duration: 2001 – 2003

Joel L. Sussman, PhD The Weizmann Institute of ScienceRehovot, Israel Structural and FunctionalAnalysis of Beta Secretase as a Potential Target forTherapeutic Intervention inAlzheimer’s DiseaseAward: $312,555 Duration: 2002 – 2005

Jordan Tang, PhDZapaq, Inc. Oklahoma City, OK Studies on Human Memapsin(Beta-Secretase): Prerequisite of Drug Design for Alzheimer’s DiseaseAward: $500,000 Duration: 2002 – 2003

Founders Program: Studies onHuman Memapsin 2 (Beta-Secretase): Drug Design forAlzheimer’s DiseaseAward: $250,000 Duration: 2002 – 2004

Rudolph E. Tanzi, PhDMassachusetts General HospitalCharlestown, MA Small Molecule Therapeutics for Alzheimer’s DiseaseAward: $340,000 Duration: 2001 – 2004

Greg R. J. Thatcher, PhDUniversity of Illinois, ChicagoChicago, IL Generation and Optimizationof NO Mimetics for Treatmentof Alzheimer’s DiseaseAward: $150,000 Duration: 2004 – 2005

Generation and Optimizationof NO mimetics for Treatmentof Alzheimer’s Disease – Part 2 Award: $130,000 Duration: 2006 – 2007

Tim Tully, PhDHelicon TherapeuticsCold Spring Harbor, NY CREB and the Discovery ofCognitive EnhancersAward: $238,780 Duration: 2001 – 2002

Duane L. Venton, PhDUniversity of Illinois, ChicagoChicago, ILA Combinatorial Search forBeta-Cyclodextrins to Abate theNeurotoxicity of Amyloid-Beta-Peptide in Alzheimer’s DiseaseAward: $311,916 Duration: 2001 – 2004

P A G E 2 0

F U N D E D P R O G R A M S

C l i n i c a l

Daniel G. Chain, PhDMindset BioPharmaceuticals(USA) Inc.New York, NYDrug Development for AD: Development of NewAntioxidantsAward: $524,018Duration: 2000 – 2002

Carl W. Cotman, PhDUniversity of California, IrvineIrvine, CAPhase I Pilot Study of Combination Antioxidants in AgingAward: $100,000Duration: 2002 – 2003

Suzanne Craft, PhDSeattle Institute forBiomedical and ClinicalResearch (SIBCR)Seattle, WAIntranasal InsulinAdministration and Memory in ADAward: $181,516Duration: 2003 – 2006

John F. DeBernardis, PhDMolecular GeriatricsCorporationVernon Hill, ILNovel Therapeutic ScreeningTechnology for Alzheimer’sDiseaseAward: $51,470Duration: 2000 – 2001

Charles S. DeCarli, MDUniversity of California, DavisSacramento, CAClinical Interpretation of MRI to Predict Conversion of Mild Cognitive Impairmentto DementiaAward: $35,000Duration: 2003 – 2004

Steven A. Johnson, PhDCortex Pharmaceuticals, Inc.Irvine, CARandomized, Double-BlindClinical Study of Ampalex(CX516) in Patients with Mild Cognitive ImpairmentAward: $247,300Duration: 2000 – 2002

Mei-Ping Kung, PhDUniversity of PennsylvaniaPhiladelphia, PAInhibitors of Beta AmyloidAggregates: Characterization ofRadio-odinated Ligands forBeta-AmyloidsAward: $263,521Duration: 2000 – 2002

Evaluation of Anti-PlaqueTreatment for Alzheimer’s DiseaseAward: $90,000Duration: 2003 – 2004

Bruce L. Miller, MDUCLA Memory and Aging CenterLos Angeles, CAUCSF Investigation of theEffects of Testosterone onCognition in Male Patientswith Mild Alzheimer’s DiseaseAward: $150,000Duration: 2003 – 2004

Peter J. Neumann, DScHarvard School of Public HealthBoston, MAPublic Attitudes TowardsGenetic Testing in Alzheimer’s DiseaseAward: $77,072Duration: 2001

John M. Ringman, MDUCLA School of MedicineLos Angeles, CAA Phase II, Double-Blind,Placebo-Controlled Study of theSafety and Tolerability of ThreeDoses of Curcumin VersusPlacebo in Patients with Mildto Moderate Alzheimer’s DiseaseAward: $299,451Duration: 2003 – 2006

Mary Sano, PhDMount Sinai Medical CenterNew York, NYEffect of High-DoseSupplements on BloodHomocyteine in Alzheimer’s DiseaseAward: $178,801Duration: 2000 – 2001

Barbara B. Sherwin, PhDMcGill UniversityVerdun, QuebecCanadaEffects of Estradiol on CognitiveFunction in Elderly Men withMild Cognitive ImpairmentAward: $186,000Duration: 1999 – 2004

• • •

D. Martin Watterson, PhD Northwestern UniversityMedical SchoolChicago, IL Ligands that SuppressNeuroinflammatory ResponsesAward: $476,278 Duration: 2001 – 2004

Novel Therapeutics TargetingNeuroinflammationAward: $140,000 Duration: 2005 – 2006

Nicholas Webster, PhDVeteran’s Medical ResearchFoundationSan Diego, CA Development of Cell-PermeableNGF MimeticsAward: $130,000 Duration: 2006 – 2007

Marta Weinstock-Rosin, PhD Hebrew University Medical CentreJerusalem, Israel Award for Major ScientificAchievement in DrugDiscovery and Development forAlzheimer’s DiseaseAward: $100,000 Duration: 2004 – 2005

Manfred Windisch, PhDJSW-ResearchForschungslabor GmbHGraz, Austria Development of a NewTreatment for Alzheimer’sDisease and Parkinson’s Diseaseusing Anti-Aggregatory Beta-Synuclein Derived PeptidesAward: $260,000 Duration: 2002 – 2004

Michael W. Wolfe, PhDBrigham and Women’s HospitalBoston, MA Helical Peptidomimetics asInhibitors of Alzheimer’sGamma-SecretaseAward: $147,067 Duration: 2000 – 2002

Tony Wyss-Coray, PhDStanford UniversityStanford, CA The TGF-Beta Pathway as aTherapeutic Target to TreatAlzheimer’s DiseaseAward: $152,232 Duration: 2003 – 2004

The TGF-Beta Pathway as aTherapeutic Target to TreatAlzheimer’s DiseaseAward: $152,300 Duration: 2004 – 2005

Ming-Ming Zhou, PhDMount Sinai Medical CenterRochester, NY Structure-based FunctionalDesign of Antagonists forGlutamate ReceptorsAward: $600,621 Duration: 2000 – 2004

Berislav Zlokovic, MD, PhDUniversity of RochesterRochester, NY Blockers of RAGE/Amyloid-Beta Interaction at the Blood Brain BarrierAward: $165,723 Duration: 2004 – 2005

Blockers of RAGE/Amyloid-Beta Interaction at the Blood Brain BarrierAward: $130,000 Duration: 2006 – 2007

P A G E 2 1

Arthur F. Kramer, PhDUniversity of IllinoisUrbana, ILInfluence of Fitness on theNeurodegenerative Function of Older AdultsAward: $433,054Duration: 2001 – 2004

Enhancing Cognitive and BrainFunction of Older AdultsThrough Fitness TrainingAward: $100,000Duration: 2005 – 2006

Thomas T. Perls, MDBoston University School of MedicineBoston, MAIdentifying Genes Predisposingto Successful Cognitive AgingAward: $522,132Duration: 1999 – 2002

John P. Blass, MD, PhDBurke Medical Research InstituteWhite Plains, NYNutritional Treatment for ADAward: $100,250Duration: 1999 – 2000

F U N D E D P R O G R A M S

P r e v e n t i o n

Jeffrey L. Cummings, MDUCLA School of MedicineLos Angeles, CAMulticenter Analysis ofHippocampal Morphology in MCIAward: $300,000Duration: 2000 – 2002

Mony deLeon, EdDNYU School of MedicineNew York, NYMRI and CSF Tau ProteinLevels: An Early Screening Testfor Alzheimer’s DiseaseAward: $85,000Duration: 1999 – 2001

Robert P. Friedland, MDCase Western ReserveUniversity School of MedicineCleveland, OHGenetic and EnvironmentalRisk Factors for Alzheimer’sDisease in Israeli ArabsAward: $50,000Duration: 1999 – 2000

Genetic and EnvironmentalRisk Factors for Alzheimer’sDisease in Israeli Arabs (Part 2)Award: $210,000Duration: 2000 – 2003

Mark A. Gluck, PhDRutgers University - NewarkNewark, NJNovel Behavioral ScreeningTools for Memory Assessment inRodents and HumansAward: $45,000Duration: 2005 – 2006

Joseph A. Helpern, PhDNYU School of MedicineNew York, NYHigh Field (3T) MRIAssessment of the BiophysicalEnvironment of the Alzheimer’s BrainAward: $150,000Duration: 2003 – 2005

David Knopman, MDMayo Clinic College of MedicineRochester, MNTelephonic Screening forCognitive ImpairmentAward: $5,828Duration: 2000

F U N D E D P R O G R A M S

E a r l y D e t e c t i o n

• • •

• • •

Ely Simon, MDNeuroTrax CorporationBayside, NYMindstreams Cognitive Testingfor Early Diagnosis andLongitudinal Follow-up ofDementia: A 3-CenterValidation StudyAward: $319,711Duration: 2003 – 2006

D. Larry Sparks, PhDSun Health Research InstituteSun City, AZA Phase II Trial Investigatingthe Effect of the HMG-CoAReductase Inhibitor Atorvastin Calcium (Lipitor) in the Treatment of Alzheimer’s DiseaseAward: $450,000Duration: 2000 – 2003

Jun Tan, PhDUniversity of South FloridaTampa, FLGreen Tea Epigallocatechin-3-Gallate (EGCG) ModulatesAmyloid Precursor Protein Cleavage and ReducesAmyloidosis in Alzheimer’sTransgenic MiceAward: $74,810Duration: 2005 – 2006

Mark H. Tuszynski, MDUniversity of California, San DiegoLa Jolla, CAA Phase I Study of NerveGrowth Factor Ex Vivo GeneTherapy for Alzheimer’s DiseaseAward: $402,113Duration: 2000 – 2003

Marc E. Weksler, PhDWeill Medical College ofCornell UniversityNew York, NYHuman Anti-A Beta Antibodies for the Treatment of Alzheimer’s DiseaseAward: $80,210Duration: 2002

John B. Zabriskie, MD The Rockefeller UniversityNew York, NY Is Variation in the Productionof TNF - In Elderly Pre-Operative Patients Predictive of Post-Operative CognitiveComplicationsAward: $86,335Duration: 1999 – 2000

P A G E 2 2

F U N D E D P R O G R A M S

G r a n t A w a r d e d C o n f e r e n c e s

• • •

• • •

A D D F / I S O A P A R T N E R S H I P P R O G R A M S

Robert N. Butler, MDInternational Longevity Center (ILC)New York, NYThe Aging Factor in Health and Disease: AnInterdisciplinary Workshop for ScientistsAward: $9,000Duration: 1999

Biomarkers of Aging WorkshopAward: $10,000Duration: 2000

Workshop on Longevity Genes: From PrimitiveOrganisms to ManAward: $5,000Duration: 2001

Workshop on Andropause: Pros and Cons of Testosteroneand its Effects on CNSAward: $10,000Duration: 2002

The ILC-ISOA-Canyon Ranch Series on CognitiveAging: Sleep DisordersAward: $7,500Duration: 2002

Workshop on: Physical, Mentaland Social Activities AffectingCognitive HealthAward: $15,000Duration: 2003

Stress: Putting the Brain Back into MedicineAward: $5,000Duration: 2004

Joyce ChaseYale University Medical SchoolNew Haven, CTCognition Enhancers, Anti-Alzheimer and NeuroprotectiveDrugs’ SymposiumAward: $5,000Duration: 2000

Avraham Fisher, PhDIsrael Institute for Biological ResearchNess-Ziona, IsraelThe XIth InternationalSymposium on CholinergicMechanisms - Function andDysfunctionAward: $5,000Duration: 2001

Robert P. Friedland, MDCase Western ReserveUniversity School of MedicineCleveland, OHInternational Symposium on Alzheimer’s Disease inMiddle EastAward: $20,000Duration: 2001

Regional Symposium onAlzheimer’s Disease and RelatedDisorders in the Middle EastAward: $3,000Duration: 2005

Alzheimer’s ResearchConsortium (ARC)New Animal Models forAlzheimer’s DiseaseAward: $200,000 Duration: 2003 – 2005

Alzheimer’s ResearchConsortium (ARC)Emory: Transgenic Rat Modelof Alzheimer’s DiseaseHarvard: Novel Fly and MouseModels for the P25/CDK5Kinase Award: $100,000Duration: 2005 – 2006

Elan Pharmaceuticals, Inc.San Diego, CA Novel Approaches to Drug Discovery for Alzheimer’s DiseaseAward: $500,000Duration: 2005 – 2008

National Institute on AgingBethesda, MD Partnership Grant betweenISOA, NIA and NINDS:Grants for Alzheimer’s Disease Drug DiscoveryAward: $300,000 Duration: 2005 – 2007

NIH Alzheimer’s DiseaseNeuroimaging InitiativeAward: $100,000 Duration: 2005

Philip Scheltens, PhDVU University Medical CenterAmsterdam,The NetherlandsFunctional Connectivity inElderly Controls andAlzheimer’s Patients UsingResting State fMRI: A Pilot StudyAward: $85,550Duration: 2003 – 2004

Gary W. Small, MDUCLA NeuropsychiatricInstituteLos Angeles, CAFDDNP-PET Imaging forEarly Detection of Alzheimer’s DiseaseAward: $200,000Duration: 2000 – 2003

Scott A. Small, MDColumbia UniversityNew York, NYImaging Mouse Models ofAlzheimer’s DiseaseAward: $92,733Duration: 2003 – 2004

D. Larry Sparks, PhDSun Health Research InstituteSun City, AZIs Elevated Serum CholesterolPredictive of Developing AD?Award: $346,372Duration: 2001 – 2006

Leon J. Thal, MDUniversity of California, San DiegoLa Jolla, CAUtility of MRI to PredictProgression from MCI to ADand Treatment Response toVitamin E and DonepezilAward: $399,890Duration: 1999 – 2004

Yanming Wang, PhDUniversity of Illinois, ChicagoChicago, ILAmyloid Probes in Aging andAlzheimer’s Disease: DualAgents for Both PET and SPECTAward: $197,000Duration: 2001 – 2005

Mousa B.H. Youdim, PhDTechnionHaifa, IsraelDevelopment and MolecularMechanism of NeuroprotectiveActivity of Novel BifucntionalCholineterase-monoamineOxidase Inhibitor-ironChelators for the Treatment ofAlzheimer’s Disease and LewyBody DiseaseAward: $75,000Duration: 2005 – 2006

P A G E 2 3

F U N D E D P R O G R A M S

P a r t n e r s h i p S p o n s o r e d C o n f e r e n c e s

• • •

Barriers to the Discovery and Development of Drugs for Alzheimer’s DiseaseDuration: 2000

Achieving Cognitive Vitalitywith AgingDuration: 2000

First Annual Investigators’ MeetingDuration: 2000

Second Annual Investigators’ MeetingDuration: 2001

Third Annual Investigators’ MeetingDuration: 2002

Neurofibrillary Tangles as aTarget for Developing NewTherapeutics for ADDuration: 2002

Apolipoprotein E as a Target forDeveloping New Therapeuticsfor Alzheimer’s DiseaseDuration: 2003

Facilitating the Development of PET Diagnostics forAlzheimer’s DiseaseDuration: 2003

Creating New Models ofAlzheimer’s DiseaseDuration: 2003

Fourth Annual Investigators’ MeetingDuration: 2003

New Directions inNeuroprotection Basics: BasicMechanisms, Molecular Targetsand Treatment StrategiesDuration: 2004

Fifth Annual Investigators’ MeetingDuration: 2004

Sixth Annual Alzheimer’s Drug Discovery ConferenceDuration: 2005

Neurogenesis as a TherapeuticStrategy for Cognitive Agingand Alzheimer’s DiseaseDuration: 2005

Ezio Giacobini, MD, PhDGeneva University HospitalsSwitzerlandSeventh InternationalGeneva/Springfield Symposiumon Advances in Alzheimer’s TherapyAward: $5,000Duration: 2002

8th InternationalMontreal/SpringfieldSymposium on Advances inAlzheimer’s TherapyAward: $5,000Duration: 2003

Yael Goshen, PhDThe Alzheimer’s Association of Israel (AAI)Ramar - Gan, IsraelThe First Israeli ConsensusConference on the Issue of The Treatment of AlzheimerPatients in IsraelAward: $10,000Duration: 2002

Illana Gozes, PhDTel Aviv UniversityTel Aviv, IsraelSummer Neuropeptide 2003 ConferenceAward: $5,000Duration: 2003

Naim M. GribaaThe Jewish Home & HospitalLifecare SystemNew York, NYAlzheimer’s ConferenceAward: $2,500Duration: 2003

Israel Hanin, PhDLoyola University ChicagoMaywood, ILAlzheimer’s and Parkinson’sDisease: New Perspectives 6th International ConferenceAward: $5,000Duration: 2003

Amos Korczyn, MD, MScTel Aviv UniversityTel Aviv, IsraelSecond International CongressOn Vascular DementiaAward: $5,000Duration: 2002

Third International Congresson Vascular DementiaAward: $5,000Duration: 2003

Jed A. Levine, MAAlzheimer’s AssociationNew York, NYBi-Annual Research SeminarSeries on Alzheimer’s Diseaseand Related Disorders of theAging Nervous System for theNew York City Research GroupAward: $5,000Duration: 2001

Bi-Annual Research SeminarSeries on Alzheimer’s Diseaseand Related Disorders of theAging Nervous System for theNew York City Research GroupAward: $5,000Duration: 2002

Mark P. Mattson, PhDNational Institute on AgingGerontology Research CenterBaltimore, MDSuccessful Aging: 30th AnnualMeeting of the American AgingAssoc., 15th Annual Meeting of the American College ofClinical GerontologyAward: $4,000Duration: 2001

Ron C. PeckNeurological DiseaseFoundationBurlingame, CAChallenging Views ofAlzheimer’s DiseaseAward: $2,500Duration: 2005

James F. Toole, PhDWake Forest Health SciencesWinston-Salem, NCPlanning for A Prospective,Randomized Study for thePrevention & Treatment ofPost-Stroke DementiaAward: $7,500Duration: 2002

Anders Wallin, MD, PhDInstitute of ClinicalNeuroscienceSwedenThe 1st Congress of theInternational Society forVascular Behavioural andCognitive Disorders (VAS-COG 2003)Award: $5,000Duration: 2003

Michael W. Weiner, MDNorthern California Institute for Research andEducation (NCIRE) San Francisco, CANeuroimaging of Alzheimer’sDisease and Related Disorders’Satellite MeetingAward: $5,000Duration: 2000

Manfred Windisch, PhDJSW-ResearchForschungslabor GmbHGraz, Austria5th International Conference onAging and Dementia - Currentand Future ConceptsAward: $5,000Duration: 2001

P A G E 2 4

Summarized Balance Sheet As of December 31, 2005

AssetsCash $ 1,074,314 Receivables and Other Assets 197,743

Total Assets $ 1,272,057

Liabilities and Net AssetsPayables and Accrued Liabilities 110,287 Net Assets 1,161,770

Total Liabilities and Net Assets $1,272,057

Summarized Operational Information For The Year Ended December 31, 2005

Support and RevenuesSupport -

Contributions and Grants $1,560,538 Revenues -

Investment and Other Income 35,437

Total Support and Revenues 1,595,975

Expenses Program-Related Services 610,148 Fund Raising and Development 147,052 Management and General 64,301

Total expenses 821,501

Change in net assets 774,474 Net assets, January 1, 2005 387,296

Net assets, December 31, 2005 $ 1,161,770

The accompanying financial information has been derived from the Foundation's 2005 Audited FinancialStatements and is presented here in condensed form.

A L Z H E I M E R ’ S D R U G D I S C O V E R Y F O U N D A T I O N

Summarized Balance Sheet As of December 31, 2005

AssetsCash $ 3,032,737 Program-Related Investments 1,398,722Property and Equipment 86,709Other Assets 72,080

Total Assets $4,590,248

Liabilities and Net AssetsPayables and Accrued Liabilities 9,830 Net Assets 4,580,418

Total Liabilities and Net Assets $4,590,248

Summarized Operational Information For The Year Ended December 31, 2005

Support and RevenuesSupport -

Contributions $ 3,451,286 Revenues -

Investment Income 57,532

Total Support and Revenues 3,508,818

Expenses Grants 2,066,353 Program-Related Services 1,825,612 Management and General / Development 264,385

Total expenses 4,156,350

Change in net assets (647,532)Net assets, January 1, 2005 5,227,950

Net assets, December 31, 2005 $ 4,580,418

The accompanying financial information has been derived from the Institute's 2005 Audited FinancialStatements and is presented here in condensed form.

I N S T I T U T E F O R T H E S T U D Y O F A G I N G , I N C .

P A G E 2 5

2 0 0 5 C O N T R I B U T I N G P A R T N E R S

Contributions of $1,000,000 and Above

We gratefully acknowledge the following partners for their generosity and support. Through their

dedication, we are able to advance our mission of accelerating drug discovery research.

Estée Lauder Family

Contributions of $100,000 and Above

Contributions of $10,000 and Above

Mr. and Mrs. Robert E.Barnhill, Jr.

Mr. and Mrs. John andLizbeth Cooney

Ms. Nancy Corzine

Dr. and Mrs. Jack and Joy Fishman

The Hazen PolskyFoundation

Ortho-McNeil Neurologics, Inc./JanssenMedical Affairs, LLC

Pfizer, Inc.

ÉLAN Pharmaceuticals, Inc. Forest Pharmaceuticals, Inc.

The Robert E. & Dorothy Z.Barnhill Family Fund

Mr. and Mrs. RandalSandler and LizabethFurman Sandler

Contributions of $1,000 and Above

Acumen Pharmaceuticals, Inc.

Bloomberg LC

The Claire & Theodore Morse Foundation

The Dalio Family Foundation Inc.

The Daniel M. and BrookeG. Neidich Foundation

Dayton Coles

Ms. Donner Selma

Estée Lauder - Oevel Plant

Graphic Expression Inc.

Martek BiosciencesCorporation

Merck & Co.

Neurochem Inc.

The Jon and SusanRotenstreich Foundation

Dr. and Mrs. Fred and Leslye Sugar

Ms. Amy G. Treitel

Wyeth Pharmaceuticals

Contributions of $100 and Above

Ms. Rachel Balsam

Ms. Nancy M. Baycroft

Mr. and Mrs. Boily Thomas

Dr. Fotini M. Dionisopoulos

Mr. and Mrs. Michale andCynthia Gibbons

The Herring FinnFoundation

The Jewish Communal Fund

The Douglas and ElizabethKoer Foundation

Dr. and Mrs. Steven Lasser

Ms. Bonnie Leisle

The Regal Family

Mr. and Mrs. Kenneth Sherman

Mr. Gary R. Silverman

The Leonard & EvelynLauder Foundation

The Pediatric Dentistry,Ltd. Staff

Other Contributing Partners

Dr. and Mrs. Stephen Deutsch

Mr. and Mrs. Philip andBarbara Falcone

Mr. and Mrs. Robert Gillen

Mr. and Mrs. Rene and Jay Glass

Ms. Rosalyn Glick

Mr. and Mrs. Samuel andLucille Irving

Mr. and Mrs. Michael andMindy Isaacs

Ms. Judith C. Isroff

Mrs. Jeanne G. Kaskey

Mr. and Mrs. Alan andNancy Kaufman

Mr. and Mrs. PeterKrulewitch

Mr. and Mrs. Nancy and Steve Lerner

Mr. and Mrs. Alfred andBonnie Margulies

Mr. and Mrs. Daniel and Ivy Marwil

Ms. Robin Pearl and Mr. Jonathan Kargman

Mr. Steven Peiser-Bus andMrs. Libby Peiser

Dr. and Mrs. Stuart Ross

Partnership Sponsored Programs

Forest Laboratories Inc.

Healthcare Dimensions, Inc.

PacifiCare Health Systems, Inc.

Zoe Finch Totten

P A G E 2 6

Fulfilling the Lauder family goal of engaging others to participate in theADDF mission has been one of the greatest rewards of my lifetime.Throughout 2005, I spoke with hundreds of people and it seemed that one out of every two that I met told me they had a loved one who was suffering from AD or past way from it. At first, they werehesitant in disclosing their experiences, but after hearing about our founda-tion they spoke more freely and offered suggestions.

With the help of many, we were able to recruit four exceptional people toour new Board of Directors. We also started an Advisory Council with threehighly experienced individuals from the healthcare and biotechnologyindustries. Additionally, we formed a Business Development Committee to assist us with public relations, special events and networking. All of these dedicated people have generously taken the time to act as ADDF ambassadors and rally others to work with us.

As part of our partnership-building and fundraising strategy, we reached outto numerous corporations, foundations and government agencies. Theyresponded so positively that we nearly doubled our anticipated financialgoal for 2005, raising $2,455,259.

Concluding my first year at the ADDF, I am convinced that workingtogether is the only way we will be able to cure AD. I am grateful for every-one who has collaborated with us and look forward to building upon ourrelationships, as well as initiating new ones, in 2006.

M E S S A G E F R O M T H E D I R E C T O R O F D E V E L O P M E N T

Suzanne GrossbergDirector of Development

Des

ign:

GR

AP

HIC

EX

PR

ES

SIO

NIN

C,

NYC

;w

ww

.tge

nyc.

com

Acclerating drug discovery for Alzheimer’s diseasethrough venture philanthropy

1414 Avenue of the Americas, Suite 1502

New York, NY 10019

P 212 935 2402 F 212 935 2408

www.AlzDiscovery.org

Alzheimer’s Drug Discovery Foundation

Alzheimer’s Drug Discovery Foundation

P A G E 3 0

ADDF GridL

P A G E 3 1

ADDF GridR